FDA approves updated Novavax COVID vaccine amid summer surge

The Food and Drug Administration (FDA) granted emergency use authorization for an updated version of the Novavax COVID-19 vaccine amid the summer surge of infections. 

The new version of the vaccine “more closely targets” variants circulating nationwide, therefore providing more protection against “serious consequences” of the virus, including hospitalization and death. It is now permitted for use in people 12 years of age and older and can target the JN.1 strain, the agency said in a news release.